Nucleai
Share
At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
Can spatial biology reveal why some patients don’t respond to immunotherapy?
Join Dr. Ettai Markovits as he shares new evidence of a predictive metabolic signature linked to immunotherapy resistance.
🎥 Watch the full webinar on demand: https://bit.ly/4ob7kbb
26/09/2025
We’re excited to bring AI-powered spatial biomarkers and diagnostics to the forefront, improving clinical decision-making and transforming patient outcomes.
Our CEO & Co-Founder, Avi Veidman, will be in Las Vegas for HLTH 2025.
:date: Going to HLTH? Let’s connect! https://hubs.li/Q03L8rMP0
🚀 Excited to kick off World CB & CDx tomorrow in Boston!
We’re looking forward to connecting with you and sharing how AI spatial proteomics can support ADC programs and help advance next-generation therapeutics.
📍 Booth #11 | 👉 Book a meeting: https://bit.ly/4msfeeg
💡 Don’t miss Dr. Ken Bloom’s talk — Sept 25 at 11:00 AM.
𝗡𝗼𝘃𝗲𝗹 𝗔𝗗𝗖 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗜𝗻𝗳𝗼𝗿𝗺 𝗬𝗼𝘂𝗿 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 & 𝗖𝗗𝘅 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆
Abstract Highlights:
✔️New research on how an antibody-drug conjugate (ADC) can bypass internalization, leading to the bystander effect
✔️How the tumor microenvironment and immune interactions could influence patient stratification and ADC-immunotherapy combo strategies
✔️How AI spatial proteomics and IHC, H&E-based quantitative biomarker scoring can give deeper insights into the MOA and efficacy of ADCs
Click here to claim your Sponsored Listing.
Category
Contact the business
Website
Address
עין זיתים 4 תל אביב, ישראל
Tel Aviv
67013
